Cerus (NASDAQ:CERS) COO Vivek Jayaraman Sells 16,667 Shares
by Scott Moore · The Cerbat GemCerus Corporation (NASDAQ:CERS – Get Free Report) COO Vivek Jayaraman sold 16,667 shares of the stock in a transaction that occurred on Friday, May 1st. The shares were sold at an average price of $3.00, for a total transaction of $50,001.00. Following the completion of the sale, the chief operating officer owned 1,673,374 shares in the company, valued at $5,020,122. This represents a 0.99% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website.
Cerus Trading Down 4.8%
Shares of NASDAQ:CERS traded down $0.13 during mid-day trading on Tuesday, reaching $2.59. The stock had a trading volume of 2,608,317 shares, compared to its average volume of 1,879,811. The firm has a market cap of $518.96 million, a PE ratio of -51.80 and a beta of 1.62. The firm has a 50 day simple moving average of $1.97 and a two-hundred day simple moving average of $1.98. The company has a current ratio of 1.63, a quick ratio of 1.06 and a debt-to-equity ratio of 0.47. Cerus Corporation has a twelve month low of $1.15 and a twelve month high of $3.15.
Cerus (NASDAQ:CERS – Get Free Report) last released its quarterly earnings data on Thursday, April 30th. The biotechnology company reported ($0.01) EPS for the quarter, beating analysts’ consensus estimates of ($0.03) by $0.02. Cerus had a negative net margin of 4.41% and a negative return on equity of 15.18%. The business had revenue of $59.89 million during the quarter, compared to analysts’ expectations of $55.68 million. On average, research analysts predict that Cerus Corporation will post -0.05 EPS for the current fiscal year.
Institutional Investors Weigh In On Cerus
Several institutional investors have recently added to or reduced their stakes in CERS. Round Rock Advisors LLC acquired a new stake in Cerus in the 4th quarter valued at approximately $545,000. IQ EQ FUND MANAGEMENT IRELAND Ltd raised its position in Cerus by 63.2% in the 3rd quarter. IQ EQ FUND MANAGEMENT IRELAND Ltd now owns 599,743 shares of the biotechnology company’s stock valued at $954,000 after buying an additional 232,218 shares during the last quarter. SG Americas Securities LLC raised its position in Cerus by 130.3% in the 3rd quarter. SG Americas Securities LLC now owns 40,062 shares of the biotechnology company’s stock valued at $64,000 after buying an additional 22,669 shares during the last quarter. Joel Isaacson & Co. LLC raised its position in Cerus by 150.0% in the 3rd quarter. Joel Isaacson & Co. LLC now owns 100,000 shares of the biotechnology company’s stock valued at $159,000 after buying an additional 60,000 shares during the last quarter. Finally, CWM LLC raised its position in Cerus by 9.3% in the 3rd quarter. CWM LLC now owns 120,906 shares of the biotechnology company’s stock valued at $192,000 after buying an additional 10,252 shares during the last quarter. 78.37% of the stock is owned by institutional investors.
Analysts Set New Price Targets
A number of analysts recently commented on the stock. Wall Street Zen upgraded shares of Cerus from a “hold” rating to a “buy” rating in a research report on Saturday. TD Cowen reiterated a “buy” rating on shares of Cerus in a research report on Monday, January 12th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Cerus in a research report on Wednesday, March 25th. Zacks Research upgraded Cerus from a “strong sell” rating to a “hold” rating in a research report on Thursday, April 30th. Finally, BTIG Research upgraded Cerus from a “neutral” rating to a “buy” rating and set a $4.00 price objective for the company in a research report on Friday. Two equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Hold” and an average price target of $4.00.
View Our Latest Stock Report on Cerus
About Cerus
Cerus Corporation is a biomedical products company dedicated to enhancing the safety of blood transfusions worldwide. Its flagship offering, the INTERCEPT Blood System, employs pathogen reduction technology designed to inactivate a broad spectrum of viruses, bacteria, and parasites in donated platelets and plasma. This approach aims to mitigate the risk of transfusion-transmitted infections and improve blood component safety for patients.
The INTERCEPT platform integrates seamlessly into existing blood center workflows, providing a one-step treatment process for collected blood products.